What question did this study set out to answer?

The study aims to determine if CPX-351 improves overall survival in molecularly defined subgroups of AML, specifically those with myelodysplasia-related mutations.

February 5, 2026Open Access

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial

Key Points

The study aims to determine if CPX-351 improves overall survival in molecularly defined subgroups of AML, specifically those with myelodysplasia-related mutations.
Conducted a phase 3 randomized trial involving 184 patients with acute myeloid leukemia (AML)
Performed DNA sequencing to categorize patients into subgroups based on gene mutations
Analyzed overall survival benefits of CPX-351 compared to the traditional 7+3 treatment regimen
Examined outcomes in relation to patients undergoing transplantation.
Two-year overall survival rates differed significantly among molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), DDX41-AML (70%)
CPX-351 significantly improved survival in AML-MR patients compared to 7+3 (median 9.7 vs 6.8 months, p=0.037)
For transplantation patients, CPX-351 improved 2-year survival (76% vs 27%; p<0.01), primarily noted in AML-MR
TP53multi showed worse survival outcomes compared to TP53single (median 3.8 vs 7.0 months; p=0.004).

Abstract

CPX-351 was approved for treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over 7+3 is confined to molecularly-defined AML subgroups by performing DNA sequencing in 184 patients enrolled in the pivotal phase 3 randomized trial. Patients were categorized hierarchically based on gene mutations: (1) TP53-AML, (2) DDX41-AML, (3) myelodysplasia-related AML (AML-MR) defined by WHO 5th edition, or (4) other-AML. TP53-AML was subclassified as single (TP53single) or multihit (TP53multi) based on the number of alleles altered via mutation, deletion, or copy-neutral loss of heterozygosity. Two-year OS differed significantly across molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), and DDX41-AML (70%) p0.001. CPX-351 improved survival in AML-MR patients compared to 7+3 (median: 9.7 vs 6.8 months, p=0.037), with no benefit in TP53-AML or other-AML. For patients undergoing transplantation, CPX-351 improved 2-year survival (76% vs 27%; p0.01), an effect primarily observed in AML-MR. Multivariable analysis confirmed the independent association with survival of both CPX-351 and HCT in AML-MR. TP53multi demonstrated significantly worse survival than TP53single (median 3.8 vs 7.0 months; p=0.004). The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, where the primary prognostic factor was allelic state. Clinical Trial Information: NCT01696084

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Shimony et al. (Mon,) studied this question.

synapsesocial.com/papers/698434dff1d9ada3c1fb392f https://doi.org/https://doi.org/10.1182/bloodadvances.2025019378

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper